3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide: A Next-Generation H+,K+-ATPase Inhibitor for Modeling Gut–Liver–Brain Axis Disorders

Introduction

Advancements in gastric acid secretion research and the study of gastric acid-related disorders have long relied on characterizing the intricate mechanisms of parietal cell proton pumps. The emergence of highly selective H+,K+-ATPase inhibitors has transformed both experimental and translational approaches. Among these, 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide (SKU: A2845) offers a unique profile, not only as a potent gastric acid secretion inhibitor but also as a versatile tool for investigating the complex interplay between gastrointestinal and neurological systems. This article explores how this compound, supplied by APExBIO, enables innovative modeling of the gut–liver–brain axis, particularly in the context of neuroinflammation and hepatic encephalopathy, providing a scientific depth and application focus distinct from previously published content.

Technical Profile and Physicochemical Properties

3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide is characterized by a molecular weight of 345.42 g/mol and the chemical formula C₁₇H₁₉N₃O₃S. Provided as a solid with a high purity (~98%, validated via HPLC and NMR), the compound is insoluble in water and ethanol, but exhibits excellent solubility (≥17.27 mg/mL) in DMSO, facilitating its use in diverse in vitro and in vivo systems. For optimal stability, storage at -20°C is recommended, avoiding prolonged solution storage. These properties make it a preferred choice for high-sensitivity, reproducible studies involving proton pump inhibition pathways.

Mechanistic Insights: H+,K+-ATPase Inhibition and Beyond

Targeting the H+,K+-ATPase Signaling Pathway

This compound functions as a potent H+,K+-ATPase inhibitor (IC₅₀ = 5.8 μM), directly impacting the terminal step of gastric acid secretion. Notably, its IC₅₀ for histamine-induced acid formation is 0.16 μM, highlighting its exceptional efficacy in antiulcer activity studies and models of peptic ulcer disease. By inhibiting the enzyme responsible for exchanging intracellular H⁺ for extracellular K⁺, it blocks acid secretion at the source, providing a robust tool for dissecting both physiological and pathophysiological processes of the gastric mucosa.

Comparative Analysis with Traditional Proton Pump Inhibitors

While existing PPIs such as ic omeprazole have established clinical and experimental roles, 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide offers several advantages for research:

• High selectivity for the H+,K+-ATPase with minimal off-target effects
• Superior stability and solubility profile for experimental reproducibility
• Enhanced suitability for advanced in vitro and in vivo modeling, including multi-organ systems

For a comprehensive protocol-driven perspective on the use of this compound in antiulcer models, see this guide. While that article provides actionable tips for accelerating research, the present work delves deeper into its mechanistic and cross-system applications, especially concerning neuroinflammatory and hepatic models.

Expanding Horizons: From Gastric Acid Secretion to the Gut–Liver–Brain Axis

Why Move Beyond Classical Antiulcer Models?

Traditional studies have focused on peptic ulcer disease model development and evaluation of gastric acid secretion inhibitors. However, emerging evidence underscores the bidirectional communication between the gut, liver, and brain, where disruptions in one compartment can trigger systemic and neurological consequences. Understanding this crosstalk is vital for developing new therapeutics for complex disorders like hepatic encephalopathy (HE) and neuroinflammatory pathologies.

Leveraging 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide in Multi-Organ Models

Recent studies, including a seminal investigation in the European Journal of Neuroscience (2025), have demonstrated how gut-targeted interventions modulate neuroinflammation in chronic HE models. In this study, chronic hepatic encephalopathy was induced in rats via bile duct ligation, and the efficacy of Bifidobacterium and fecal microbiota transplantation (FMT) was assessed using [18F]PBR146 PET imaging of neuroinflammation. While FMT failed to attenuate neuroinflammation, Bifidobacterium reduced neuroinflammatory signals, highlighting the importance of gut–liver–brain communication and the role of gastric acid modulation in these pathways.

By integrating 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide into such models, researchers can:

• Precisely modulate gastric acid secretion to study downstream effects on gut microbiota composition and systemic inflammation
• Evaluate the impact of proton pump inhibition on the progression or mitigation of neuroinflammation and behavioral deficits in HE and related disorders
• Dissect the contribution of gastric acid to the integrity of the gut barrier and its influence on the gut–liver–brain axis

Distinct Value: Bridging Mechanistic and Translational Gaps

Unlike prior articles that focus on practical workflow integration or conventional antiulcer paradigms—such as Solving Laboratory Challenges with 3-(quinolin-4-ylmethylamino)..., which addresses reproducibility and assay compatibility—this article provides a deeper mechanistic exploration and extends the application horizon to multi-organ and neuroinflammatory models. By situating this compound at the interface of gastric, hepatic, and neural research, we offer a novel lens on experimental design, enabling a more holistic understanding of systemic disease mechanisms.

Case Study: Modeling Hepatic Encephalopathy with Advanced H+,K+-ATPase Inhibition

Hepatic encephalopathy is a neuropsychiatric syndrome associated with advanced liver disease, systemic inflammation, and neuroinflammation. Recent PET imaging studies have revealed that alterations in the gut environment—driven by microbiota or pharmacological interventions—can profoundly shape neuroinflammatory responses (see European Journal of Neuroscience, 2025). Integrating a highly selective H+,K+-ATPase inhibitor such as 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide into these models enables researchers to:

• Systematically map the effect of reduced gastric acid on gut microbiota and its downstream consequences on liver inflammation and brain function
• Test the interdependency of proton pump inhibition, gut barrier function, and neuroinflammatory biomarkers, such as TSPO expression and cytokine profiles
• Develop refined antiulcer agent for research protocols that also address comorbid hepatic and neurological endpoints

This systems-level modeling approach remains relatively unexplored in existing literature, setting this article apart from more narrowly focused content such as advanced mechanistic reviews or practical assay guides.

Practical Considerations: Experimental Design and Product Handling

To maximize experimental reproducibility and translational relevance, consider the following best practices when employing the A2845 kit in multi-system models:

• Prepare fresh stock solutions in DMSO immediately before use to preserve compound integrity
• Adopt dosing regimens that parallel physiologically relevant exposure windows for both gastric and systemic endpoints
• Utilize validated endpoints, including PET imaging biomarkers, cytokine assays, and behavioral assessments, to capture multi-organ cross-talk

By following these guidelines, researchers can harness the full potential of this compound for both classical and next-generation research paradigms.

Conclusion and Future Outlook

3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide (SKU: A2845) stands at the forefront of gastric acid secretion inhibitor research, offering unmatched precision for both antiulcer activity study and advanced modeling of systemic disease. By bridging gastric, hepatic, and neural research domains, this compound empowers investigators to unravel the complexities of the gut–liver–brain axis and its role in disorders such as hepatic encephalopathy. As the field moves toward integrative, mechanism-driven models, the application of highly selective H+,K+-ATPase inhibitors like those offered by APExBIO will be pivotal in driving both scientific discovery and translational innovation.

For those interested in further reading on advanced integration with gut–liver–brain axis models and mechanistic nuances, see this article, which explores related but distinct aspects of cross-system research. Our current analysis extends these insights by providing a unified mechanistic and translational framework, ensuring researchers can design studies that address both molecular and systemic endpoints in gastric acid-related and neuroinflammatory disorders.